10-K: TYRA Biosciences Advances Precision Oncology Pipeline

TYRA Biosciences reports significant progress in its FGFR-targeted precision medicine pipeline, advancing three lead candidates into Phase 2 trials and detailing financial results for fiscal year 2025.

Summary

• TYRA Biosciences is a clinical-stage biotechnology company focused on developing next-generation precision medicines for targeted oncology and genetically defined conditions, leveraging Fibroblast Growth Factor Receptor (FGFR) biology.
• The company's proprietary SNP platform enables rapid and precise drug design through iterative molecular SNPshots.
• The lead program, oral dabogratinib (formerly TYRA-300), is currently in three Phase 2 trials: SURF303 for low-grade upper tract urothelial carcinoma (LG-UTUC), SURF302 for intermediate risk non-muscle invasive bladder cancer (IR NMIBC), and BEACH301 for achondroplasia (ACH) in children.
• Initial clinical proof-of-concept results for oral dabogratinib in the SURF301 study (metastatic urothelial carcinoma) demonstrated encouraging anti-tumor activity and was generally well-tolerated, with infrequent FGFR2and FGFR1-associated toxicities.
• TYRA-430, an FGFR4/3 biased inhibitor for FGF19+ hepatocellular carcinoma (HCC), commenced its global Phase 1 clinical trial (SURF431) in April 2025.
• TYRA-200, an FGFR1/2/3 inhibitor designed to address acquired resistant mutations in FGFR2-driven intrahepatic cholangiocarcinoma (ICC), commenced its global Phase 1 clinical trial (SURF201) in December 2023.
• The net loss for the year ended December 31, 2025, was $119.9 million, an increase from $86.5 million in 2024.
• As of December 31, 2025, the company had an accumulated deficit of $371.3 million.
• Cash, cash equivalents, and marketable securities totaled $256.0 million as of December 31, 2025, which is expected to fund operations through at least 2027.
• Oral dabogratinib received Orphan Drug Designation (July 2023) and Rare Pediatric Disease Designation (January 2024) from the FDA for the treatment of ACH.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive update. While financial losses increased, this is typical for a clinical-stage biotech with an expanding pipeline. The significant clinical progress with dabogratinib and other programs, coupled with a solid cash runway through 2027, indicates strong operational execution and potential for future value creation, despite the increased burn.

Positives

• Advancing lead candidate, oral dabogratinib, into three Phase 2 trials (SURF303, SURF302, BEACH301) for large market indications in urothelial cancers and skeletal dysplasia conditions.
• Initial clinical proof-of-concept for oral dabogratinib in SURF301 showed encouraging anti-tumor activity and was generally well-tolerated, with infrequent FGFR2and FGFR1-associated toxicities.
• Dabogratinib demonstrated a 50% response rate (5/10) in FGFR3 positive metastatic urothelial carcinoma patients at 90 mg daily, with a 100% disease control rate in the SURF301 study.
• No hyperphosphatemia, ALT or AST increases, discontinuations, or dose reductions were reported at dabogratinib doses equal to or lower than 60 mg QD in SURF301.
• TYRA-430 and TYRA-200 programs are progressing in Phase 1 clinical trials, expanding the pipeline.
• The proprietary SNP platform enables rapid and precise drug design, aiming to overcome toxicity and resistance liabilities of prior generation pan-FGFR inhibitors.
• Received Orphan Drug Designation (July 2023) and Rare Pediatric Disease Designation (January 2024) for dabogratinib for achondroplasia, potentially qualifying for a priority review voucher.
• Strong cash, cash equivalents, and marketable securities balance of $256.0 million as of December 31, 2025, expected to fund operations through at least 2027.
• Increased research and development investment by $22.8 million in 2025, reflecting active pipeline development and commitment to advancing product candidates.

Negatives

• Incurred significant net losses, with a net loss of $119.9 million for 2025, an increase from $86.5 million in 2024.
• Accumulated deficit of $371.3 million as of December 31, 2025, indicating a history of operating losses.
• The company is in early stages of development with no products approved for commercial sale and has not generated any revenue to date.
• Reliance on third parties for manufacturing and clinical trials introduces risks related to supply, quality, and timely execution.
• Faces significant competition from larger, better-funded pharmaceutical and biotechnology companies.
• Further development of oral dabogratinib for metastatic urothelial carcinoma is not planned, despite positive Phase 1 data, due to prioritized focus on other market opportunities.
• Interest and other income decreased by $4.9 million in 2025, attributed to lower interest rates and reduced cash balances.

Risks

• Early stage of development, limited operating history, and no approved products make it difficult for investors to evaluate current business and likelihood of success.
• Expects to incur significant net losses for the foreseeable future.
• Requires substantial additional capital; failure to obtain necessary capital could delay, limit, reduce, or terminate development programs or commercialization efforts.
• Preclinical and clinical development is a lengthy, expensive process with uncertain outcomes, and early results are not necessarily predictive of future results.
• Difficulties enrolling patients in clinical trials could delay or adversely affect clinical development activities.
• Use of product candidates could be associated with side effects, adverse events, or other safety risks, potentially delaying or precluding approval.
• Reliance on third parties for manufacturing product candidates increases the risk of insufficient quantities or unacceptable costs.
• Reliance on third parties to conduct clinical trials; failure to successfully carry out duties could delay development programs.
• Faces significant competition from companies with greater financial resources and established market presence.
• Inability to obtain and maintain patent protection for product candidates or if the scope of protection is not sufficiently broad, competitors could commercialize similar products.
• The trading price of common stock could be highly volatile.
• The proprietary SNP platform is innovative and unproven, and may not lead to approved products of commercial value.
• May expend limited resources to pursue a particular product candidate and fail to capitalize on more profitable opportunities.
• Orphan drug designation does not guarantee market exclusivity or faster development/regulatory review.
• FDA and other foreign equivalents may not accept data from clinical trials conducted outside of the United States.
• Interim, topline, and preliminary data from preclinical studies and clinical trials may change as more patient data become available.
• May attempt to secure accelerated approval, but it may not be granted or maintained, requiring additional studies.
• Disruptions at the FDA and other government agencies (e.g., funding shortages, staffing limitations) could hinder timely development and approval.
• Changes in methods of product candidate manufacturing or formulation may result in additional costs or delays.
• No marketing and sales organization; significant resources needed to develop these capabilities or rely on third parties.
• Commercial success depends on market acceptance and adequate reimbursement from governmental authorities and health insurers.
• Future growth may depend on operating in foreign markets, subject to additional regulatory burdens and risks.
• Operating results may fluctuate significantly, making future results difficult to predict.
• Dependent on the services of management and other clinical and scientific personnel; inability to retain or recruit could harm business.
• Needs to continue to grow the size and capabilities of the organization, which may be difficult to manage.
• Subject to various federal, state, and foreign healthcare laws and regulations, increasing compliance costs.
• Actual or perceived failures to comply with applicable data protection, privacy, and security laws could adversely affect business.
• Recently enacted legislation (e.g., Inflation Reduction Act of 2022, One Big Beautiful Bill Act) and future healthcare reform measures may increase costs and affect pricing.
• Use of potent chemical agents and hazardous materials carries risks of claims relating to improper handling, storage, or disposal.
• Product liability lawsuits could result in substantial liabilities and require limiting commercialization.
• Required to report adverse medical events; failure to do so could result in sanctions.
• Information technology systems, or those of third parties, may fail or suffer security breaches.
• Business could be affected by litigation, government investigations, and enforcement actions.
• Employees and independent contractors may engage in misconduct or other improper activities.
• May engage in strategic transactions that could impact liquidity, increase expenses, and distract management.
• Unstable market and economic conditions and adverse developments with respect to financial institutions may have serious adverse consequences.
• Changes in tax law may materially adversely affect financial condition.
• Ability to use net operating loss carryforwards and other tax attributes may be limited under Section 382 of the U.S. Internal Revenue Code.
• May be subject to claims challenging the inventorship of patents and other intellectual property.
• Inability to protect the confidentiality of trade secrets would harm business and competitive position.
• May not be successful in obtaining necessary rights to product components and processes for the development pipeline through acquisitions and in-licenses.
• Could be subject to securities class action litigation.
• Disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
• Subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations.
• Business disruptions (e.g., earthquakes, power shortages, pandemics) could seriously harm future revenue and financial condition.

Future Outlook

The company expects to advance oral dabogratinib toward three potential registrational trials in LG-UTUC, IR NMIBC, and ACH if Phase 2 studies are successful. The first patient in SURF303 (LG-UTUC) is anticipated to be dosed in 2026. Initial three-month CR data from SURF302 (IR NMIBC) is expected by the end of the first half of 2026, and initial data from the safety sentinel cohort of BEACH301 (ACH) is expected in the second half of 2026. The company anticipates incurring significant expenses and increasing operating losses for the foreseeable future as development activities progress, but believes existing cash, cash equivalents, and marketable securities will fund operations through at least 2027.

Management Comments

• "Our mission is to improve outcomes for patients living with cancer and genetically defined conditions."
• "We are executing on our mission by focusing on advancing our pipeline and building a leading company around FGFR biology."
• "We believe that a sharp focus on efficiently generating these three key empirical datasets for compound candidates enables us to balance speed with the robust identification of pivotal insights to rapidly and precisely iterate the design of our novel molecular structures."
• "We believe this data suggests that 90 mg QD is the optimal dose for further evaluation in the mUC setting, however, no further development is planned at this time due to our prioritized focus on what we believe are more attractive market opportunities." (Regarding SURF301 mUC data)
• "We believe that the full development potential for oral dabogratinib may cover the entire spectrum of disease in urothelial carcinoma and may represent a large opportunity given the high prevalence of FGFR3 mutations and the potential to treat earlier disease."
• "By engaging FGFR3 selectively at higher, safe doses, oral dabogratinib may have the potential to meaningfully improve height, health and functional outcomes beyond what can be achieved with current therapies in development for children with ACH, HCH, Turner syndrome, SHOX deficiency, other FGFR3-driven genetic syndromes and idiopathic short stature."
• "We believe TYRA-430 has the potential to address a significant unmet need in HCC, where there are no approved biomarker-driven, targeted therapies."
• "Positive data in this setting [FGFR2-driven ICC resistant to previous FGFR inhibitors], where other FGFR inhibitors have not succeeded, would potentially provide confidence in our belief that addressing acquired resistance may prolong the duration of responses, and ultimately PFS, in the FGFR-naive setting." (Regarding TYRA-200)
• "We consider our relationship with our employees to be good."

Industry Context

StockSavvy.ai notes that TYRA Biosciences operates in the highly competitive and rapidly advancing fields of precision oncology and rare disease biotechnology. The focus on FGFR biology is a validated approach, with several first-generation FGFR inhibitors already approved by the FDA (e.g., erdafitinib, pemigatinib, futibatinib). TYRA's SNP platform aims to differentiate its candidates by addressing the limitations of these earlier therapies, specifically targeting improved selectivity and activity against acquired resistance mutations, which is a critical unmet need in cancer treatment. The company's strategy to pursue both oncology and rare skeletal conditions (like achondroplasia) with a single lead candidate (dabogratinib) demonstrates a diversified approach to maximizing asset value, a common strategy among biotech firms seeking to broaden market opportunities. The increasing regulatory scrutiny on drug pricing, as evidenced by the Inflation Reduction Act and the "One Big Beautiful Bill Act," presents a challenging environment for all pharmaceutical companies, potentially impacting future revenue and profitability.

Comparison to Industry Standards

• Dabogratinib (FGFR3) is designed for greater selectivity for FGFR3 over FGFR1, FGFR2, and FGFR4 to minimize off-target side effects, aiming for potential clinical advantages over less selective first-generation compounds like erdafitinib.
• Erdafitinib (a pan-FGFR inhibitor) in a Phase 3 metastatic urothelial carcinoma trial reported hyperphosphatemia in over 70% of patients, 72% dose interruptions, 69% dose reductions, and 14% treatment discontinuations, highlighting the toxicity challenges of less selective inhibitors.
• Dabogratinib at doses equal to or lower than 60 mg QD exhibited favorable interim safety results in SURF301, with no hyperphosphatemia, ALT or AST increases, discontinuations, or dose reductions reported, suggesting a potentially superior safety/tolerability profile at these doses compared to erdafitinib.
• In achondroplasia, BioMarin's Voxzogo (a daily injected C-natriuretic peptide analog) achieved 5.66 cm/year in average height velocity (AHV), a 1.40 cm improvement over baseline, in a pivotal study. Ascendis' Yuviwel (TransCon CNP), a weekly injected prodrug, showed similar efficacy in Phase 3.
• BridgeBio's infigratinib (a daily oral, low-dose FGFR1/2/3 inhibitor) achieved 5.96 cm/yr AHV and a 1.74 cm/yr improvement over baseline in a Phase 3 study for achondroplasia, but adult doses above 0.33 mg/kg were limited by hyperphosphatemia.
• Dabogratinib, in preclinical models (1.2 mg/kg in mice, roughly equivalent to 0.5 mg/kg in children), demonstrated significant increases in body length (+17.9%), femur length (+22.6%), tibia length (+33.0%), and L4-L6 length (+23.5%) in mice, suggesting potential for meaningful height improvement beyond current therapies.
• BioMarin disclosed that prolonged treatment with Voxzogo could result in a final adult height improvement of 26 cm or more, but this is still potentially 20 cm less than average height for adult males without achondroplasia, indicating a remaining unmet need that dabogratinib aims to address.
• TYRA-200 is designed as an FGFR1/2/3 inhibitor active against nearly all clinically identified acquired resistant mutations, aiming to overcome the problem of disease progression due to polyclonal resistance that limits the efficacy of existing pan-FGFR inhibitors like Incyte's Pemazyre and Taiho Oncology's Lytgobi in intrahepatic cholangiocarcinoma.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently subject to any material legal proceedings.
• May be involved in legal proceedings or subject to claims incident to the ordinary course of business from time to time.

Related Party Transactions

• In connection with the February 2024 Private Placement, issued 4,780,846 shares of common stock and pre-funded warrants to purchase 2,243,737 shares of common stock to related parties, resulting in aggregate gross proceeds of approximately $91.4 million.
• On October 18, 2024, entered into an exchange agreement with certain stockholders (who were related parties at the time) to exchange 3,000,000 shares of common stock for pre-funded warrants to acquire an aggregate of 3,000,000 shares of common stock.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings and stock price volatility, with no anticipated cash dividends.
• Employees benefit from competitive total rewards, including a 401(k) plan with company match, and the company reports a good relationship with its 87 full-time employees, 67 of whom are in R&D.
• Patients stand to benefit from the potential development of next-generation precision medicines for serious conditions like urothelial cancers, achondroplasia, hepatocellular carcinoma, and intrahepatic cholangiocarcinoma, addressing significant unmet medical needs.
• Future customers (if products are approved) will be impacted by the company's ability to achieve market acceptance, secure adequate coverage, and obtain favorable reimbursement policies.
• Creditors are not explicitly detailed, but future debt financing could introduce restrictive covenants.
• Suppliers and contractors, particularly third-party manufacturers and CROs, are critical to the company's operations, and their performance or any disruptions could impact development timelines and costs.

Next Steps

• Advance oral dabogratinib toward three potential registrational trials in LG-UTUC, IR NMIBC, and ACH if Phase 2 studies are successful.
• Anticipate dosing the first patient in SURF303 (LG-UTUC) in 2026.
• Report initial three-month CR data from SURF302 (IR NMIBC) by the end of the first half of 2026.
• Report initial data from the safety sentinel cohort of BEACH301 (ACH), including 6-month average height velocity (AHV) results and interim safety, in the second half of 2026.
• Continue to leverage the SNP platform for the discovery and development of additional preclinical programs.
• Publish final Phase 1 results from SURF301 in a future scientific publication.

Key Dates

Recommendation

TYRA Biosciences is making solid clinical progress with its FGFR-targeted pipeline, particularly with dabogratinib advancing into multiple Phase 2 trials for significant indications. The positive early data and strategic focus on overcoming limitations of first-generation inhibitors are encouraging. However, the company is still in early development stages, incurring substantial and increasing net losses, and will require significant additional capital. While the current cash runway extends through 2027, the inherent risks of clinical development, intense competition, and regulatory uncertainties warrant a cautious "Hold" recommendation. Investors should monitor upcoming Phase 2 data readouts for SURF302 and BEACH301 in 2026, which will be critical catalysts for future valuation.

Keywords

FGFR, precision medicine, oncology, achondroplasia, urothelial cancer, NMIBC, UTUC, hepatocellular carcinoma, cholangiocarcinoma, dabogratinib, TYRA-300, TYRA-430, TYRA-200, SNP platform, biotechnology, clinical-stage, rare disease, drug development, SEC filing, 10-K